Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
4/5 보강
TL;DR
Tofacitinib should be considered for the treatment of severe AA, alopecia totalis, and alopECia universalis; tofacit inib dose response will be better defined by randomized controlled trials.
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: AA experienced a higher percent change in SALT score than did patients with alopecia totalis or alopecia universalis (81
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[LIMITATIONS] The retrospective nature of the data, the relatively small number of patients, and lack of a control group are limitations. [CONCLUSION] Tofacitinib should be considered for the treatment of severe AA, alopecia totalis, and alopecia universalis; tofacitinib dose response will be better defined by randomized controlled trials.
📑 코퍼스 인용 관계
· 인용됨 96
📑 인용한 논문 (6) ▾
- Systemic Inflammation Marker Alterations in Severe Alopecia Areata Patients Treated with J… Journal of clinical medicine · 2026
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Area… American journal of clinical dermatology · 2026
- Case Report: Successful treatment of pediatric alopecia universalis with ritlecitinib afte… Frontiers in medicine · 2025
- Efficacy of Oral Tofacitinib in Alopecia Areata, Alopecia Totalis, and Alopecia Universali… Cureus · 2025
- Alopecia Areata: Pathogenesis, Diagnosis, and Therapies. MedComm · 2025
- Exploring the Use of Topical Tofacitinib in Pediatric Alopecia Totalis. International journal of trichology · 2025
연도별 인용 (2016–2026) · 합계 334
OpenAlex 토픽 ·
Hair Growth and Disorders
Skin and Cellular Biology Research
Dermatology and Skin Diseases
Abstract 🌐 Abstract
[BACKGROUND] Alopecia areata (AA) is a common autoimmune disorder. There are no reliably effective therapies for AA.
[OBJECTIVE] We sought to evaluate the safety and efficacy of the Janus kinase 1/3 inhibitor, tofacitinib, in a series of patients over an extended period of time.
[METHODS] This is a retrospective study of patients age 18 years or older with AA with at least 40% scalp hair loss treated with tofacitinib. The primary end point was the percent change in Severity of Alopecia Tool (SALT) score during treatment.
[RESULTS] Ninety patients met inclusion criteria. Of 65 potential responders to therapy, defined as those with alopecia totalis or alopecia universalis with duration of current episode of disease of 10 years or less or alopecia areata, 77% achieved a clinical response, with 58% of patients achieving greater than 50% change in SALT score over 4 to 18 months of treatment. Patients with AA experienced a higher percent change in SALT score than did patients with alopecia totalis or alopecia universalis (81.9% vs 59.0%). Tofacitinib was well tolerated, and there were no serious adverse events.
[LIMITATIONS] The retrospective nature of the data, the relatively small number of patients, and lack of a control group are limitations.
[CONCLUSION] Tofacitinib should be considered for the treatment of severe AA, alopecia totalis, and alopecia universalis; tofacitinib dose response will be better defined by randomized controlled trials.
[OBJECTIVE] We sought to evaluate the safety and efficacy of the Janus kinase 1/3 inhibitor, tofacitinib, in a series of patients over an extended period of time.
[METHODS] This is a retrospective study of patients age 18 years or older with AA with at least 40% scalp hair loss treated with tofacitinib. The primary end point was the percent change in Severity of Alopecia Tool (SALT) score during treatment.
[RESULTS] Ninety patients met inclusion criteria. Of 65 potential responders to therapy, defined as those with alopecia totalis or alopecia universalis with duration of current episode of disease of 10 years or less or alopecia areata, 77% achieved a clinical response, with 58% of patients achieving greater than 50% change in SALT score over 4 to 18 months of treatment. Patients with AA experienced a higher percent change in SALT score than did patients with alopecia totalis or alopecia universalis (81.9% vs 59.0%). Tofacitinib was well tolerated, and there were no serious adverse events.
[LIMITATIONS] The retrospective nature of the data, the relatively small number of patients, and lack of a control group are limitations.
[CONCLUSION] Tofacitinib should be considered for the treatment of severe AA, alopecia totalis, and alopecia universalis; tofacitinib dose response will be better defined by randomized controlled trials.
Tofacitinib should be considered for the treatment of severe AA, alopecia totalis, and alopECia universalis; tofacit inib dose response will be better defined by randomized controlled trials.
APA 7
Liu, L. Y., Craiglow, B. G., Dai, F., & King, B. A. (2017). Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.. Journal of the American Academy of Dermatology, 76(1), 22-28. https://doi.org/10.1016/j.jaad.2016.09.007
Vancouver
Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. Jour. Amer. Acad. Derm.. 2017;76(1):22-28. doi:10.1016/j.jaad.2016.09.007
AMA 11
Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. Jour. Amer. Acad. Derm.. 2017;76(1):22-28. doi:10.1016/j.jaad.2016.09.007
Chicago
Liu, L. Y., Craiglow, B. G., Dai, F., and King, B. A.. 2017. "Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients." Journal of the American Academy of Dermatology 76 (1): 22-28. https://doi.org/10.1016/j.jaad.2016.09.007
MLA 9
Liu, L. Y., et al. "Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients." Journal of the American Academy of Dermatology, vol. 76, no. 1, 2017, pp. 22-28. doi:10.1016/j.jaad.2016.09.007.
PMID
27816293 ↗
추출된 의학 개체 (NER)
전체 NER 표 보기
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 질환 | alopecia areata
|
원형 탈모증 | dict | 3 | |
| 질환 | alopecia areata
|
원형 탈모증 | dict | 3 | |
| 질환 | alopecia areata
|
원형 탈모증 | dict | 3 | |
| 해부 | scalp
|
두피 | dict | 1 | |
| 해부 | scalp
|
두피 | dict | 1 | |
| 해부 | scalp
|
두피 | dict | 1 |
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 5/8 (63%)
· 참조 0편 · 후속 5편
이 논문을 인용한 후속 연구 20
- Alopecia areata.
- Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management.
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type A…
- Alopecia Areata: a Comprehensive Review of Pathogenesis and Management.
- Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options.
- Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients.
- The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meanin…
- JAK inhibitors in dermatology: The promise of a new drug class.
- Alopecia Areata: Current Treatments and New Directions.
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm.
- JAK Inhibitors for Treatment of Alopecia Areata.
- Immune modulation of hair follicle regeneration.
- Baricitinib for the Treatment of Alopecia Areata.
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata.
- The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Res…
- Tofacitinib for the treatment of lichen planopilaris: A case series.
- The current state of knowledge of the immune ecosystem in alopecia areata.
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata.
- Development of the Scalp Hair Assessment PRO™ measure for alopecia areata.
- New and Emerging Therapies for Alopecia Areata.
같은 제1저자의 인용 많은 논문 (5)
- Health-related quality of life (HRQoL) among patients with alopecia areata (AA): A systematic review.
- Alopecia areata is associated with impaired health-related quality of life: A survey of affected adults and children and their families.
- Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients.
- Ruxolitinib for the treatment of severe alopecia areata.
- Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- 피나스테리드가 전립선암 발생에 미치는 영향.
- COVID-19의 50가지 이상의 장기 후유증: 체계적 문헌고찰 및 메타분석.
- 양성 전립선 비대증의 임상적 진행에 대한 doxazosin, finasteride 및 병용 요법의 장기 효과.
- 양성 전립선 비대증 환자에서 finasteride의 효과. The Finasteride Study Group.
- 양성 전립선 비대증 남성에서 급성 요폐의 위험과 수술적 치료 필요성에 대한 finasteride의 효과. Finasteride Long-Term Efficacy and Safety Study Group.
- 원형 탈모에 대한 전장유전체 연관성 연구는 선천면역과 적응면역 모두의 관여를 시사한다.
📖 비슷한 OA 논문 — 같은 카테고리, 무료 전문 가능
-
Alopecia areata.
TL;DRAlopecia areata is difficult to manage medically, but recent advances in understanding the molecular mechanisms have revealed new treatments and the possibility of remission in the…
-
Epidemiology and burden of alopecia areata: a systematic review.
TL;DRAA is the most prevalent autoimmune disorder and the second most prevalent hair loss disorder after androgenetic alopecia, and the lifetime risk in the global population is approxi…
-
Two Phase 3 Trials of Baricitinib for Alopecia Areata.
TL;DRIn two phase 3 trials involving patients with severe alopecia areata, oral baricitinib was superior to placebo with respect to hair regrowth at 36 weeks.
-
Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics.
TL;DRAlthough a variety of medical, surgical, light‐based and nutraceutical treatment options are available to slow or reverse the progression of AGA, it can be challenging to select ap…
-
Hair follicle immune privilege and its collapse in alopecia areata.
TL;DRA key goal for effective AA management is the re‐establishment of a functional HF IP, which will also provide superior protection from disease relapse, and may confer increased sus…